Glucagon News and Research

RSS

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.

28 Aug 2024

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.

27 Aug 2024

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion

27 Aug 2024

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Researchers discuss the role of enhanced visceral adipose tissue metabolism in mediating weight loss by glucagon-like peptide-1 drugs.

26 Aug 2024

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Researchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.

26 Aug 2024

Understanding the health benefits of polyphenols through bitter taste receptors

Bioactive compounds like polyphenols and their health benefits have long captured public attention and interest.

23 Aug 2024

New research challenges belief that weight loss drugs only reduce appetite

A study carried out in St Vincent's University Hospital (SVUH) Dublin challenges the belief that weight loss medications such as Ozempic, Wegovy or Monjaro work just by promoting satiety and making you eat less.

22 Aug 2024

High-protein diets: How they affect weight, energy, and blood sugar levels

Researchers review the effects of dietary protein on energy intake, appetite, and postprandial glycemia.

21 Aug 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

Gut microbiota plays a crucial role in type 2 diabetes management

Research reveals the intricate role of gut microbiota in type 2 diabetes, highlighting personalized therapeutic strategies and the complexity of microbial interactions with antidiabetic drugs.

15 Aug 2024

FDA clears UAB startup's TIX100 for clinical trials

The University of Alabama at Birmingham startup TIXiMED, Inc., has obtained clearance from the United States Food and Drug Administration to proceed to clinical trials under an Investigational New Drug for TIX100, its novel oral Type 1 diabetes drug.

31 Jul 2024

Weight loss guaranteed! But what impact on your diet? A review of GLP-1 and GIP/GLP-1 interventions

Researchers reviewed studies on dietary impacts of GLP-1 and GIP/GLP-1 receptor agonists in obesity and T2D patients, finding significant caloric reduction but limited evaluation of dietary composition.

29 Jul 2024

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.

29 Jul 2024

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

Researchers highlight the unprecedented success of GLP-1-based multi-receptor drugs in achieving substantial weight loss and improved health outcomes, potentially replacing bariatric surgery for obesity treatment.

28 Jul 2024

How diet affects metabolism and the gut microbiome

In a recent review, researchers explored advances in molecular nutrition, focusing on pharmaceutical and dietary interventions for energy balance and their interactions with the gut microbiome. They also discussed emerging dietary patterns and the implications of microbiome research on nutrition.

28 Jul 2024

New review highlights advances in diabetes research and treatment

A new paper surveying advances in diabetes pathogenesis and treatment explores the complex factors contributing to the onset and progression of the disease, suggesting that an understanding of these dynamics is key to developing targeted interventions to reduce the risk of developing diabetes and managing its complications.

25 Jul 2024

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

23 Jul 2024

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) - prescription medications sold under popular drug names like Ozempic and Wegovy - in the United States.

22 Jul 2024

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.

18 Jul 2024

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

17 Jul 2024